Mark Sulkowski, MD

CRS:

JHU

Role:

Investigators

Position:

Site Investigator

Email:

msulkows@jhmi.edu
  • Chair, Hepatitis TSG (Dec 2016)
  • Chair, Steering Committee of Hepatitis TSG (Dec 2016)
  • SC Representative, Scientific Agenda Steering Committee (Dec 2014)
  • Member, HBV Cure Working Group of the HEP TSG (Mar 2015)
  • Co-Chair, NASH Focus Group of the ITSG/HEPTSG (April 2016)
  • Chair 5329
  • Vice-Chair, 5360
  • Co-chair 5334s
  • Investigator, 5335s

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5349: Rifapentine-containing treatment shortening regimens...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5384: A Phase II, Randomized, Open-Label Trial of a...

Study Description A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious disease...

Read More

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

The Pharmacokinetics, Safety and Acceptability of New...

PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...

Read More